Walgreens sells shares of drug distributor Cencora
Drugstore chain Walgreens Boots Alliance Inc. (WBA) on Thursday said it had sold shares of drug distributor Cencora Inc. (COR) for approximately $424 million. Walgreens also entered into a share repurchase by Cencora, formerly known as AmerisourceBergen, for proceeds of roughly $250 million. Walgreens said its ownership of Cencora's common stock fell due to the repurchase by Cencora, "but remains at approximately 15%." The drugstore chain said it planned to use the proceeds to repay debt and for general business operations. "The transaction is another decisive action to further simplify the company's portfolio, while improving cash management," Walgreens said, adding that it "remains fully committed to the strategic, mutually beneficial relationship with Cencora," a partner with Walgreens since 2013.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-09-23 1924ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters